Recent Investment Analysts’ Ratings Updates for Orthofix Medical (OFIX)

Orthofix Medical (NASDAQ: OFIX) has recently received a number of price target changes and ratings updates:

• 5/22/2026 – Orthofix Medical had its price target lowered by Barrington Research from $17.00 to $15.00. They now have an “outperform” rating on the stock.
• 5/22/2026 – Orthofix Medical had its price target lowered by Stifel Nicolaus from $18.00 to $15.00. They now have a “buy” rating on the stock.
• 5/21/2026 – Orthofix Medical had its “hold” rating reaffirmed by TD Cowen.
• 5/21/2026 – Orthofix Medical had its price target lowered by Canaccord Genuity Group Inc. from $20.00 to $18.00. They now have a “buy” rating on the stock.
• 5/2/2026 – Orthofix Medical was downgraded by Wall Street Zen from “buy” to “hold”.
• 4/21/2026 – Orthofix Medical had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 4/10/2026 – Orthofix Medical had its “outperform” rating reaffirmed by Barrington Research. They now have a $17.00 price target on the stock.

Insiders Place Their Bets

In related news, insider Jorge Andres Cedron sold 3,743 shares of the stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $12.82, for a total value of $47,985.26. Following the transaction, the insider owned 59,006 shares of the company’s stock, valued at $756,456.92. This represents a 5.97% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Lucas Vitale sold 4,269 shares of the stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $11.92, for a total value of $50,886.48. Following the completion of the transaction, the insider directly owned 160,449 shares in the company, valued at $1,912,552.08. This trade represents a 2.59% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders bought 189,896 shares of company stock worth $2,293,970. 2.70% of the stock is owned by corporate insiders.

Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company’s core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix’s product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.